Spravato: First Monotherapy FDA Approved for Treatment-Resistant MDD
Treatment-resistant depression (TRD) remains a significant challenge for clinicians and patients alike, often requiring innovative strategies beyond traditional antidepressants. A groundbreaking step in addressing this unmet need came with the FDA approval of SPRAVATO® (esketamine) nasal spray as the first monotherapy specifically for adults with TRD.Â
SPRAVATO® was initially approved by the FDA in March 2019 as an adjunct therapy for adults with TRD. In 2025, the FDA extended its approval to include monotherapy for adults with TRD, based on robust clinical evidence demonstrating its efficacy and safety. This marked a pivotal moment, as SPRAVATO® became the first monotherapy specifically designed for TRD.
WATCH FOLLOWING YOUTUBE VIDEO FOR DETAILS:
The video has summarized this topic in following sections:
- Esketamine FDA Approval History.
- FDA Indications
- When to Avoid?
- How to Dose?
- Clinical Study Supporting the Approval.
- Common Adverse Events
Here is one slide from above presentation, on how to dose this medication:
FOR ACADEMY MEMBERS:
This lecture series is organized into the following 10 chapters:
- Atypical Antipsychotics
- Lithium
- Thyroid Hormones
- L-Methylfolate
- Lamotrigine
- Stimulants
- Buspirone
- Pramipexole
- S-Adenosyl Methionine (SAMe)
- Low Dose Naltrexone
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
- Monthly Insights: Gain access to our monthly sessions featuring the latest on recent publications, new medication approvals, FDA updates, and more. (Monthly Insights)
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2025 All Rights Reserved.
